HOME >> BIOLOGY >> NEWS
Max Planck researchers make a breakthrough in plant stem cell research

Totipotent stem cells allow plants to build new organs throughout their whole life. But it has been unclear how hormones and genetic factors work together to prevent plants from having growth that is either stunted, or uncontrolled and tumor-like. Scientists from the Max Planck Institute for Developmental Biology have now uncovered a feedback mechanism, involving a growth-enhancing hormone and a regulatory protein, which controls the number of stem cells the plant produces. (Nature, December 22, 2005). The results are of great importance for all of stem cell research.

All above ground parts of a plant - leaves, stem, flowers, and seeds - ultimately are derived from cells of a small tissue at the tip of the shoot. Biologists call this tissue the "apical meristem", and it contains totipotent stem cells that are active throughout the life of the plant. Unlike the stem cells of animals, which can only produce specific kinds of tissue after the animal is past its embryonic stage, plant stem cells remain their totipotency and, therefore plants can continue growing over many years, developing new organs.

But this ability comes at a price. If the number of meristematic stem cells increases too quickly, then there could be uncontrolled growth, similar to cancer. On the other hand, if the stem cell pool shrinks too quickly, the plant could have stunted growth. In order to stay alive and reproduce, the plant needs to find the right balance in the number of its stem cells. Two regulatory mechanisms were found to be important for this process. The first involves growth-promoting hormones like auxin and cytokinin, known already for more than half a century. The second involves genetic factors, which were discovered at the University of Tübingen, Germany about a decade ago. Here it was shown that a gene called WUSCHEL has a key influence on how many cells in the apical meristem actually stay stem cells. However, until now, it was unclear how hormones and regulatory
'"/>

Contact: Dr. Jan Lohmann
jan.lohmann@tuebingen.mpg.de
497-071-601-1405
Max-Planck-Gesellschaft
22-Dec-2005


Page: 1 2 3

Related biology news :

1. 454 Life Sciences and Max Planck publish sequence of one million base pairs
2. Max Planck researchers win part of Descartes Research Prize 2005
3. Global commitment of Max Planck researchers
4. Four Max Planck Partner Groups starting in India
5. First Max Planck Partner Institute in China
6. Innovative tagging technique may help researchers better protect fish stocks
7. Penn researchers discover how key protein stops inflammation
8. ASU researchers partner with UOP to make biofuel for military jets a reality
9. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
10. Penn researchers discover pathway that eliminates genetic defects in red blood cells
11. U-M researchers find family of on switches that cause prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Max Planck researchers make breakthrough plant stem cell research

(Date:6/18/2015)... 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market announces that its Wocket® smart ... "Money on the Mark", scheduled to air on WABC Radio ... 20 th . The broadcast air- time ... to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
(Date:6/30/2015)... BOSTON , June 30, 2015  Juniper ... company focused on developing therapeutics that address unmet ... CFO George Elston will present at ... , Wednesday, July 8, 2015Time: , 4:45 PM ... NYWebcast (live & archive): , www.juniperpharma.com, under  ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile ... to achieve faster flow rates in comparison to nylon or polyethersulfone (PES). ... to allow easy liquid flow while trapping particulates as small as 0.2 micron ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Matrix Marketing ... that it has hired Gem Swartz to head up its account management department as ... director. Both Gem and Amanda bring senior account management and delivery expertise to the ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
Cached News: